1% af patienterne i kliniske undersøgelser, behandlet i op til 1 år med etoricoxib 30, 60 eller 90 mg dagligt.
Hepatic effects Elevations of alanine aminotransferase (ALT) and/ or aspartate aminotransferase (AST) (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials treated for up to one year with etoricoxib 30, 60 and 90 mg daily.